Evidence map›Paper›PMID 37139148›Full record

ArticleFrontiers in oncology2023

Tongyi Zhang, Hongwei Wang, Zhiwei Cai, Siqi Zhang, Chongyi Jiang

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Characterization ofTranslational lung cancer research · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Fusion genes in pancreatic tumors.Trends in cancer · 2024
    Review
  7. Review
  8. Cancers · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Tongyi ZhangDepartment of General Surgery, Huadong Hospital, Fudan University, Shanghai, China.
Hongwei WangDepartment of Hepato-Biliary-Pancreatic Surgery, Huadong Hospital, Fudan University, Shanghai, China.
Zhiwei CaiDepartment of Hepato-Biliary-Pancreatic Surgery, Huadong Hospital, Fudan University, Shanghai, China.
Siqi ZhangThe Medical Department, 3D Medicines Inc., Shanghai, China.
Chongyi JiangDepartment of General Surgery, Huadong Hospital, Fudan University, Shanghai, China.
Huadong Hospital · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While

Indexed as

pancreatic cancerpralsetinibRET fusionRET inhibitorstarget therapy

Identifiers

PMID37139148
PMCPMC10149926
OpenAlexW4366207695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.